Limited-Time Offer for New Patients: Start GLP-1 Medical Weight Loss & Treat Stubborn Belly Fat with 4 Complimentary BTL Vanquish ME Treatments ($2,600 Value).
Skip to main content

The Treatment That's a Game Changer for Women with Urinary Incontinence

Emsella

The Treatment That’s a Game Changer for Those With Urinary Incontinence

BTL EMSELLA™– the only device available to target a woman’s entire pelvic floor region for the treatment of incontinence. This unique technology revolutionizes the women’s intimate health and wellness category by providing those suffering from incontinence with a completely non-invasive option.  The “chair” design of the device itself allows women to remain fully clothed for treatment, with no pain or downtime, so patients can walk out immediately following treatment.

“This is truly revolutionary as up until now, invasive treatments have been the only option to effectively address these serious issues.

Statistics show that approximately 35% of women worldwide are affected by urinary incontinence, which presents itself in three forms: stress (leakage during physical activity), urge (strong & sudden), and mixed (combination of stress and urge).  Incontinence is often a result of child birth and/or the natural aging process, and can have a dramatic effect on a woman’s quality of life.  Women often report having to give up exercise and a decrease in self-confidence and intimacy as a result of incontinence.

Harnessing the power of HIFEM (High-Intensity Focused Electromagnetic) technology, BTL EMSELLA™  stimulates the entire pelvic floor at once—with a single session providing thousands of supramaximal pelvic floor muscle contractions, comparable to thousands of Kegels.

A recent clinical study demonstrated that 95% of patients treated reported satisfaction and significant improvement in their quality of life following six treatments with BTL EMSELLA™.  Additionally, 67% of treated patients totally eliminated or decreased the use of hygienic pads in day-to-day life.

For optimal results a series of six, twice –weekly, 28 minute treatments are required.  Call Weight Loss and Vitality to learn more and schedule your complimentary phone consultation – 571 550 9000.

Author
David Bauder David J. Bauder, PA-C David Bauder, PA-C, is a certified physician assistant and the assistant medical director at Weight Loss and Vitality in Manassas and Alexandria, Virginia, Washington, DC; and Gaithersburg, MD. He enjoys helping patients optimize their physical and mental health to improve their overall well-being. He earned his physician assistant degree from the University of Texas Health Science Center at San Antonio. Afterward, he gained admission into the reputable graduate program for physician assistant studies at the University of Nebraska Health Science Center in Omaha. David has over 26 years of experience working as a physician assistant. He’s practiced in podiatry, family medicine, emergency medicine, general surgery, urgent care, and functional medicine.

You Might Also Enjoy...

A digital medical-style illustration showing a glowing translucent human figure in profile against a blue futuristic backgrou

How AOD-9604 Supports Fat Metabolism

AOD 9604 is a synthetic peptide fragment derived from human growth hormone that has shown potential in early research to support fat metabolism and weight loss, though its long-term safety, efficacy, and regulatory status remain uncertain.
TB-500 illustration showing muscle tissue repair, reduced inflammation, and improved blood flow in a flexed arm.

How TB-500 Promotes Recovery and Angiogenesis

TB-500 is a synthetic fragment of thymosin beta-4 associated with tissue repair and angiogenesis, but human evidence is limited, it is not FDA-approved, and its safety and effectiveness remain uncertain.
Retatrutide illustration showing digestive system and metabolic pathways related to weight loss and metabolism.

How Retatrutide Impacts Weight Loss and Metabolism

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors that has shown significant weight loss and metabolic benefits in trials, but it is not yet FDA-approved and remains available only in clinical studies.
PT-141 illustration showing brain-driven sexual arousal and libido enhancement between two figures with neural activation.

How PT-141 Enhances Libido and Sexual Function

PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist that enhances sexual desire in premenopausal women with HSDD, with strong clinical evidence, though use in men remains off-label and less established.